<?xml version='1.0' encoding='utf-8'?>
<document id="15762767"><sentence text="Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine."><entity charOffset="29-40" id="DDI-PubMed.15762767.s1.e0" text="almotriptan" /><entity charOffset="44-53" id="DDI-PubMed.15762767.s1.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.15762767.s1.e0" e2="DDI-PubMed.15762767.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15762767.s1.e0" e2="DDI-PubMed.15762767.s1.e1" /></sentence><sentence text="The pharmacokinetics of almotriptan are linear over a range of oral doses up to 200mg in healthy volunteers"><entity charOffset="24-35" id="DDI-PubMed.15762767.s2.e0" text="almotriptan" /></sentence><sentence text=" The compound has a half-life of approximately 3 hours" /><sentence text=" Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69"><entity charOffset="1-12" id="DDI-PubMed.15762767.s4.e0" text="Almotriptan" /></sentence><sentence text="1%" /><sentence text=" Maximal plasma concentrations are achieved between 1" /><sentence text="5 and 4 hours after dose administration; however, within 1 hour after administration, plasma concentrations are approximately 68% of the value at 3 hours after administration" /><sentence text=" Food does not significantly affect almotriptan absorption"><entity charOffset="36-47" id="DDI-PubMed.15762767.s8.e0" text="almotriptan" /></sentence><sentence text=" Almotriptan is not highly protein bound and is extensively distributed in the body"><entity charOffset="1-12" id="DDI-PubMed.15762767.s9.e0" text="Almotriptan" /></sentence><sentence text=" Approximately 50% of an almotriptan dose is excreted unchanged in the urine; this is the predominant single mechanism of elimination"><entity charOffset="25-36" id="DDI-PubMed.15762767.s10.e0" text="almotriptan" /></sentence><sentence text=" Renal clearance is mediated, in part, through active tubular secretion, while the balance of the almotriptan dose is metabolised to inactive compounds"><entity charOffset="98-109" id="DDI-PubMed.15762767.s11.e0" text="almotriptan" /></sentence><sentence text=" The predominant route of metabolism is via monoamine oxidase-A, and cytochrome P450 (CYP) mediated oxidation (via CYP3A4 and CYP2D6) occurs to a minor extent"><entity charOffset="44-53" id="DDI-PubMed.15762767.s12.e0" text="monoamine" /></sentence><sentence text=" Almotriptan clearance is moderately reduced in elderly subjects, but the magnitude of this effect does not warrant a dose reduction"><entity charOffset="1-12" id="DDI-PubMed.15762767.s13.e0" text="Almotriptan" /></sentence><sentence text=" Sex has no significant effect on almotriptan pharmacokinetics"><entity charOffset="34-45" id="DDI-PubMed.15762767.s14.e0" text="almotriptan" /></sentence><sentence text=" Almotriptan pharmacokinetic parameters do not differ between adolescents and adults, and absorption is not affected during a migraine attack"><entity charOffset="1-12" id="DDI-PubMed.15762767.s15.e0" text="Almotriptan" /></sentence><sentence text=" As expected, renal dysfunction results in reduced clearance of almotriptan"><entity charOffset="64-75" id="DDI-PubMed.15762767.s16.e0" text="almotriptan" /></sentence><sentence text=" Patients with moderate-to-severe renal dysfunction should use the lowest dose of almotriptan and the total daily dose should not exceed 12"><entity charOffset="82-93" id="DDI-PubMed.15762767.s17.e0" text="almotriptan" /></sentence><sentence text="5 mg" /><sentence text=" Similar dosage recommendations are valid for patients with hepatic impairment, based on the clearance mechanisms for almotriptan"><entity charOffset="118-129" id="DDI-PubMed.15762767.s19.e0" text="almotriptan" /></sentence><sentence text=" Drug-drug interaction studies were conducted between almotriptan and the following compounds: fluoxetine, moclobemide, propranolol, verapamil and ketoconazole"><entity charOffset="54-65" id="DDI-PubMed.15762767.s20.e0" text="almotriptan" /><entity charOffset="95-105" id="DDI-PubMed.15762767.s20.e1" text="fluoxetine" /><entity charOffset="107-118" id="DDI-PubMed.15762767.s20.e2" text="moclobemide" /><entity charOffset="120-131" id="DDI-PubMed.15762767.s20.e3" text="propranolol" /><entity charOffset="133-142" id="DDI-PubMed.15762767.s20.e4" text="verapamil" /><entity charOffset="147-159" id="DDI-PubMed.15762767.s20.e5" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e0" e2="DDI-PubMed.15762767.s20.e0" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e0" e2="DDI-PubMed.15762767.s20.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e0" e2="DDI-PubMed.15762767.s20.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e0" e2="DDI-PubMed.15762767.s20.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e0" e2="DDI-PubMed.15762767.s20.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e0" e2="DDI-PubMed.15762767.s20.e5" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e1" e2="DDI-PubMed.15762767.s20.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e1" e2="DDI-PubMed.15762767.s20.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e1" e2="DDI-PubMed.15762767.s20.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e1" e2="DDI-PubMed.15762767.s20.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e1" e2="DDI-PubMed.15762767.s20.e5" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e2" e2="DDI-PubMed.15762767.s20.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e2" e2="DDI-PubMed.15762767.s20.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e2" e2="DDI-PubMed.15762767.s20.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e2" e2="DDI-PubMed.15762767.s20.e5" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e3" e2="DDI-PubMed.15762767.s20.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e3" e2="DDI-PubMed.15762767.s20.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e3" e2="DDI-PubMed.15762767.s20.e5" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e4" e2="DDI-PubMed.15762767.s20.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s20.e4" e2="DDI-PubMed.15762767.s20.e5" /></sentence><sentence text=" No significant pharmacokinetic or pharmacodynamic interactions with almotriptan were observed for fluoxetine or propranolol"><entity charOffset="69-80" id="DDI-PubMed.15762767.s21.e0" text="almotriptan" /><entity charOffset="99-109" id="DDI-PubMed.15762767.s21.e1" text="fluoxetine" /><entity charOffset="113-124" id="DDI-PubMed.15762767.s21.e2" text="propranolol" /><pair ddi="false" e1="DDI-PubMed.15762767.s21.e0" e2="DDI-PubMed.15762767.s21.e0" /><pair ddi="false" e1="DDI-PubMed.15762767.s21.e0" e2="DDI-PubMed.15762767.s21.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s21.e0" e2="DDI-PubMed.15762767.s21.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s21.e1" e2="DDI-PubMed.15762767.s21.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s21.e1" e2="DDI-PubMed.15762767.s21.e2" /></sentence><sentence text=" Almotriptan clearance was reduced, to a modest degree, by moclobemide and verapamil, which was consistent with the contribution of monoamine oxidase-A and CYP3A4 to the metabolic clearance of almotriptan"><entity charOffset="1-12" id="DDI-PubMed.15762767.s22.e0" text="Almotriptan" /><entity charOffset="59-70" id="DDI-PubMed.15762767.s22.e1" text="moclobemide" /><entity charOffset="75-84" id="DDI-PubMed.15762767.s22.e2" text="verapamil" /><entity charOffset="132-141" id="DDI-PubMed.15762767.s22.e3" text="monoamine" /><entity charOffset="193-204" id="DDI-PubMed.15762767.s22.e4" text="almotriptan" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e0" e2="DDI-PubMed.15762767.s22.e0" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e0" e2="DDI-PubMed.15762767.s22.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e0" e2="DDI-PubMed.15762767.s22.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e0" e2="DDI-PubMed.15762767.s22.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e0" e2="DDI-PubMed.15762767.s22.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e1" e2="DDI-PubMed.15762767.s22.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e1" e2="DDI-PubMed.15762767.s22.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e1" e2="DDI-PubMed.15762767.s22.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e1" e2="DDI-PubMed.15762767.s22.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e2" e2="DDI-PubMed.15762767.s22.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e2" e2="DDI-PubMed.15762767.s22.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e2" e2="DDI-PubMed.15762767.s22.e4" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e3" e2="DDI-PubMed.15762767.s22.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s22.e3" e2="DDI-PubMed.15762767.s22.e4" /></sentence><sentence text=" Although ketoconazole has a greater effect on almotriptan clearance than verapamil, no dosage adjustment is required when almotriptan is given with these drugs"><entity charOffset="10-22" id="DDI-PubMed.15762767.s23.e0" text="ketoconazole" /><entity charOffset="47-58" id="DDI-PubMed.15762767.s23.e1" text="almotriptan" /><entity charOffset="74-83" id="DDI-PubMed.15762767.s23.e2" text="verapamil" /><entity charOffset="123-134" id="DDI-PubMed.15762767.s23.e3" text="almotriptan" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e0" e2="DDI-PubMed.15762767.s23.e0" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e0" e2="DDI-PubMed.15762767.s23.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e0" e2="DDI-PubMed.15762767.s23.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e0" e2="DDI-PubMed.15762767.s23.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e1" e2="DDI-PubMed.15762767.s23.e1" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e1" e2="DDI-PubMed.15762767.s23.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e1" e2="DDI-PubMed.15762767.s23.e3" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e2" e2="DDI-PubMed.15762767.s23.e2" /><pair ddi="false" e1="DDI-PubMed.15762767.s23.e2" e2="DDI-PubMed.15762767.s23.e3" /></sentence><sentence text="" /></document>